NCT05141240View on ClinicalTrials.gov

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

CompletedOBSERVATIONAL
Enrollment

4,650

Participants

Timeline

Start Date

April 15, 2020

Primary Completion Date

June 15, 2020

Study Completion Date

June 15, 2020

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Ribiciclib

Participants who initiated CDK4/6i therapy

DRUG

Palbociclib

Participants who initiated CDK4/6i therapy

DRUG

Abemaciclib

Participants who initiated CDK4/6i therapy

Trial Locations (1)

07936

Novartis Investigational site, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY